CY2016013I2 - Φαρμακευτικες συνθεσεις που περιλαμβανουν βαλσαρτανη και αναστολεις nep - Google Patents

Φαρμακευτικες συνθεσεις που περιλαμβανουν βαλσαρτανη και αναστολεις nep

Info

Publication number
CY2016013I2
CY2016013I2 CY2016013C CY2016013C CY2016013I2 CY 2016013 I2 CY2016013 I2 CY 2016013I2 CY 2016013 C CY2016013 C CY 2016013C CY 2016013 C CY2016013 C CY 2016013C CY 2016013 I2 CY2016013 I2 CY 2016013I2
Authority
CY
Cyprus
Prior art keywords
pharmaceutical compositions
compositions containing
nep inhibitors
containing valsartan
valsartan
Prior art date
Application number
CY2016013C
Other languages
English (en)
Other versions
CY2016013I1 (el
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23373410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2016013(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY2016013I2 publication Critical patent/CY2016013I2/el
Publication of CY2016013I1 publication Critical patent/CY2016013I1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY2016013C 2002-01-17 2016-05-18 Φαρμακευτικες συνθεσεις που περιλαμβανουν βαλσαρτανη και αναστολεις nep CY2016013I1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34966002P 2002-01-17 2002-01-17
PCT/EP2003/000415 WO2003059345A1 (en) 2002-01-17 2003-01-16 Pharmaceutical compositions comprising valsartan and nep inhibitors

Publications (2)

Publication Number Publication Date
CY2016013I2 true CY2016013I2 (el) 2016-10-05
CY2016013I1 CY2016013I1 (el) 2016-10-05

Family

ID=23373410

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20071101386T CY1106959T1 (el) 2002-01-17 2007-10-25 Φαρμακευτικες συνθεσεις που περιλαμβανουν βαλσαρτανη και αναστολεις nep
CY2016013C CY2016013I1 (el) 2002-01-17 2016-05-18 Φαρμακευτικες συνθεσεις που περιλαμβανουν βαλσαρτανη και αναστολεις nep

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20071101386T CY1106959T1 (el) 2002-01-17 2007-10-25 Φαρμακευτικες συνθεσεις που περιλαμβανουν βαλσαρτανη και αναστολεις nep

Country Status (29)

Country Link
EP (1) EP1467728B1 (el)
JP (2) JP4820056B2 (el)
KR (2) KR100984939B1 (el)
CN (2) CN1615134A (el)
AT (1) ATE370732T1 (el)
AU (1) AU2003206738C1 (el)
BE (1) BE2016C025I2 (el)
BR (2) BRPI0306907B8 (el)
CA (1) CA2472399C (el)
CO (1) CO5600999A2 (el)
CY (2) CY1106959T1 (el)
DE (1) DE60315795T2 (el)
DK (1) DK1467728T3 (el)
EC (1) ECSP045190A (el)
ES (1) ES2290429T3 (el)
FR (1) FR16C0019I2 (el)
HU (1) HUS1600024I1 (el)
IL (2) IL162661A0 (el)
LU (1) LU93074I2 (el)
MX (1) MXPA04006917A (el)
NL (1) NL300811I2 (el)
NO (2) NO333191B1 (el)
NZ (1) NZ533968A (el)
PL (1) PL212318B1 (el)
PT (1) PT1467728E (el)
RU (1) RU2334513C3 (el)
SI (1) SI1467728T1 (el)
WO (1) WO2003059345A1 (el)
ZA (1) ZA200405117B (el)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2384346C2 (ru) * 2004-06-23 2010-03-20 Зольвай Фармасьютиклз Гмбх Фармацевтические композиции, содержащие nep-ингибиторы, ингибиторы эндогенной эндотелинпродуцирующей системы и антагонисты at1-рецептора
AU2005318365B2 (en) 2004-12-24 2011-02-03 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
WO2007045663A2 (en) * 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
WO2007051007A2 (en) * 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (en) * 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
CZ300801B6 (cs) * 2006-06-07 2009-08-12 Helvetia Pharma A.S. Kompozice s valsartanem v pevných lékových formách
MY151993A (en) 2007-01-12 2014-07-31 Novartis Ag Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid
GB0708507D0 (en) 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
PL2295035T3 (pl) * 2007-11-06 2016-11-30 Podwójne działanie kompozycji farmaceutycznych opartych na superstrukturach antagonisty/blokera receptora angiotensyny (arb) oraz inhibitora obojętnej endopeptydazy (nep)
CN101774941A (zh) 2009-01-13 2010-07-14 浙江九洲药业股份有限公司 2-酰基氨基-3-联苯基丙酸的制备及拆分方法
ES2582395T3 (es) 2009-05-28 2016-09-12 Novartis Ag Derivados aminobutíricos sustituidos como inhibidores de neprilisina
MX2011012628A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
EP2609075B1 (en) 2010-08-23 2016-03-16 Novartis AG Process for the preparation of intermediates for the manufacture of nep inhibitors
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
MX378867B (es) * 2012-08-24 2025-03-11 Novartis Ag Inhibidores de la nep para el tratamiento de enfermedades caracterizadas por el ensanchamiento o remodelacion auricular.
WO2014126972A1 (en) 2013-02-14 2014-08-21 Novartis Ag Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy
JP6295277B2 (ja) 2013-02-14 2018-03-14 ノバルティス アーゲー Ｎｅｐ（中性エンドペプチダーゼ）阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体
CN104230865B (zh) * 2013-06-13 2018-01-09 上海翰森生物医药科技有限公司 联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
HRP20200060T1 (hr) 2013-08-26 2020-04-03 Novartis Ag Nova uporaba
JP2016530282A (ja) 2013-08-26 2016-09-29 ノバルティス アーゲー 新規使用
WO2016029828A1 (zh) * 2014-08-27 2016-03-03 上海翰森生物医药科技有限公司 AHU-377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用
WO2016037098A1 (en) * 2014-09-04 2016-03-10 Concert Pharmaceuticals, Inc. Deuterated sacubitril
WO2016037552A1 (zh) * 2014-09-09 2016-03-17 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
CN105503760A (zh) * 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
PL3218351T3 (pl) 2014-11-14 2019-12-31 Zentiva K.S. Sposób wytwarzania, wyodrębniania i oczyszczania farmaceutycznie dopuszczalnych postaci AHU-377
WO2016086798A1 (zh) * 2014-12-03 2016-06-09 上海翰森生物医药科技有限公司 Nep抑制剂结晶型游离酸、钙盐多晶型及其制备方法和应用
EP3443960A1 (en) * 2014-12-08 2019-02-20 Crystal Pharmatech Co., Ltd. Crystalline form of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof
CN105693543B (zh) * 2014-12-15 2018-08-10 四川海思科制药有限公司 沙库比曲类衍生物、其药物组合物、制备方法及用途
CN104826115A (zh) * 2015-04-19 2015-08-12 浙江巨泰药业有限公司 一种抗心衰药物组合物及其制备方法
CN106138069A (zh) * 2015-04-21 2016-11-23 刘春丽 作为治疗来自非角化复层上皮组织的不适的局部药剂的1-二仲丁基膦酰基戊烷
HRP20230480T1 (hr) 2015-05-11 2023-07-21 Novartis Ag Režim doziranja sakubitrila i valsartana za liječenje zatajenja srca
US20180140579A1 (en) 2015-05-29 2018-05-24 Novartis Ag Sacubitril and valsartan for treating metabolic disease
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
CN106397248A (zh) * 2015-08-03 2017-02-15 深圳信立泰药业股份有限公司 一种lcz696结晶粉末及其制备方法
WO2017037577A1 (en) 2015-08-28 2017-03-09 Novartis Ag New use
WO2017036420A1 (zh) * 2015-09-06 2017-03-09 常州方楠医药技术有限公司 含沙库比曲和缬沙坦的药用组合物及其制备方法
CN105348209B (zh) 2015-12-09 2017-12-26 浙江天宇药业股份有限公司 一种抗心衰药lcz696的制备方法
EP3386945A1 (en) 2015-12-11 2018-10-17 Zentiva, K.S. Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method
US10722471B2 (en) 2016-02-03 2020-07-28 Novartis Ag Galenic formulations of organic compounds
AU2017215530B2 (en) 2016-02-03 2019-09-12 Novartis Ag Galenic formulations of organic compounds
PL3524250T3 (pl) 2016-10-08 2025-11-12 Wuhan Ll Science And Technology Development Co., Ltd. Kompozycja farmaceutyczna zawierająca inhibitor neutralnej endopeptydazy (NEP) i pochodną estru azylsartanu oraz jej zastosowanie w leczeniu chorób sercowo-naczyniowych
WO2018211479A1 (en) 2017-05-19 2018-11-22 Lupin Limited Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof
WO2019008485A1 (en) * 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
MX391562B (es) 2017-07-28 2025-03-21 Synthon Bv Composicion farmaceutica que comprende sacubitril y valsartan
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CN110237071B (zh) 2018-03-09 2022-03-22 武汉朗来科技发展有限公司 药物制剂及其应用
KR20210032437A (ko) 2018-08-23 2021-03-24 노파르티스 아게 심부전의 치료를 위한 신규한 약제학적 용도
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
WO2021158084A1 (ko) * 2020-02-07 2021-08-12 보령제약 주식회사 하이브리드 화합물 및 그 제조방법
KR20200020746A (ko) 2020-02-07 2020-02-26 보령제약 주식회사 하이브리드 화합물 및 그 제조방법
KR20210101164A (ko) 2020-02-07 2021-08-18 보령제약 주식회사 하이브리드 화합물 및 그 제조방법
KR20210120560A (ko) 2020-03-27 2021-10-07 주식회사 유영제약 고함량의 주성분을 포함하는 정제 및 그 제조방법
KR20220091767A (ko) 2020-12-24 2022-07-01 주식회사 보령 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
KR20240099023A (ko) 2022-12-20 2024-06-28 주식회사 티에치팜 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 심혈관 질환 예방 또는 치료용 약학적 조성물
JP2026501945A (ja) 2022-12-20 2026-01-19 ティーエイチファーム コーポレーション ナトリウム－グルコース共輸送体－２阻害剤およびアンジオテンシンｉｉ受容体遮断剤を含む経口用薬学製剤
CN116687921A (zh) * 2023-06-14 2023-09-05 宁波大学 沙库巴曲缬沙坦类物质在制备神经毒性和认知障碍类药物的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0498361A3 (en) * 1991-02-06 1992-09-02 Schering Corporation Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
CA2168066A1 (en) * 1995-02-08 1996-08-09 James R. Powell Treatment of hypertension and congestive heart failure
EP1267855A2 (en) * 2000-04-03 2003-01-02 Bristol-Myers Squibb Company Vasopeptidase inhibitors to treat isolated systolic hypertension
SK18062002A3 (sk) * 2000-06-22 2003-07-01 Novartis Ag Pevné orálne farmaceutické kompozície obsahujúce valsartan
DK1313714T3 (da) * 2000-07-19 2008-12-15 Novartis Ag Valsartansalte
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives

Also Published As

Publication number Publication date
NO20043380L (no) 2004-10-07
CA2472399A1 (en) 2003-07-24
KR100984939B1 (ko) 2010-10-01
CN1615134A (zh) 2005-05-11
EP1467728A1 (en) 2004-10-20
NO2016009I2 (no) 2016-05-18
NO333191B1 (no) 2013-03-25
MXPA04006917A (es) 2004-12-06
KR20100057704A (ko) 2010-05-31
PL369773A1 (en) 2005-05-02
CA2472399C (en) 2012-02-21
AU2003206738B2 (en) 2006-12-21
PL212318B1 (pl) 2012-09-28
KR20040078127A (ko) 2004-09-08
NL300811I2 (el) 2016-07-27
PT1467728E (pt) 2007-11-14
FR16C0019I2 (fr) 2017-12-08
BE2016C025I2 (el) 2022-05-17
AU2003206738C1 (en) 2020-01-30
NZ533968A (en) 2006-10-27
RU2334513C3 (ru) 2017-10-24
CY1106959T1 (el) 2012-01-25
EP1467728B1 (en) 2007-08-22
KR100984939B9 (ko) 2024-07-17
CN102091330A (zh) 2011-06-15
NO2016009I1 (no) 2016-05-18
ECSP045190A (es) 2004-08-27
SI1467728T1 (sl) 2008-02-29
BR0306907A (pt) 2004-12-21
ATE370732T1 (de) 2007-09-15
ZA200405117B (en) 2005-08-31
JP4820056B2 (ja) 2011-11-24
BR122018015003B8 (pt) 2021-07-27
LU93074I2 (fr) 2016-07-18
ES2290429T3 (es) 2008-02-16
BRPI0306907B1 (pt) 2018-10-30
BRPI0306907B8 (pt) 2021-05-25
CN102091330B (zh) 2015-04-08
JP2005514441A (ja) 2005-05-19
IL162661A0 (en) 2005-11-20
RU2004125178A (ru) 2005-06-10
JP2011207898A (ja) 2011-10-20
AU2003206738A1 (en) 2003-07-30
IL162661A (en) 2010-11-30
BR122018015003B1 (pt) 2018-11-21
CO5600999A2 (es) 2006-01-31
HUS1600024I1 (hu) 2016-06-28
DE60315795D1 (de) 2007-10-04
CY2016013I1 (el) 2016-10-05
DK1467728T3 (da) 2007-12-27
RU2334513C2 (ru) 2008-09-27
WO2003059345A1 (en) 2003-07-24
FR16C0019I1 (el) 2016-06-24
DE60315795T2 (de) 2008-06-05

Similar Documents

Publication Publication Date Title
CY2016013I2 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν βαλσαρτανη και αναστολεις nep
NO20054789D0 (no) Sammensetninger inneholdende piperaciliin og tazobactam nytting for injeksjon
CY2018009I2 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
CY2014001I1 (el) Συνδυασμος αζελαστινης και φλουτικαζονης
CY2013043I1 (el) Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv
ATE435859T1 (de) Gyraseinhibitoren und deren verwendungen
CY2014033I1 (el) Παραγωγα κινολινης και η χρηση τους ως μυκοβακτηριακων αναστολεων
EE05509B1 (et) Aktiveeritud polalkleenglkoolpolmeer ja seda sisaldavad kompositsioonid
EP1513825A4 (en) ANTITU-CULINARY MEDICAMENT: COMPOSITIONS AND METHODS
DK1425019T3 (da) Farmaceutisk sammensætning omfattende et androgen
IL173639A (en) Ppar-activating compound and pharmaceutical composition containing same
IS7948A (is) Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
ATE401800T1 (de) Hochintensive süssstoffzusammensetzung und deren abgabe
FR2834693B1 (fr) Emballage presentoir
EP1603593A4 (en) PHARMACEUTICAL COMPOSITION
DK1354873T3 (da) Perindoaprilsalt og farmaceutiske sammensætninger indeholdende dette
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
DK1587478T3 (da) Farmaceutisk sammensætning
EP1512408A4 (en) ANTIBACTERIAL AGENT AND ANTIBACTERIAL COMPOSITION
DE60312049D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
PT1558263E (pt) Composicao farmaceutica de libertacao prolongada
PL361518A1 (pl) Zastosowanie substancji oraz kompozycja farmaceutyczna
DE60330764D1 (de) Pharmazeutische zusammensetzung enthaltend einen lipase - inhibitor und glucomannan
ATE489069T1 (de) Mundpflegezusammensetzungen und -verfahren
EP1541139A4 (en) DRUG COMPOSITION WITH NF-KAPPA B HEMMER